bms-986012

mAbexperimental

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0

Earliest trial started Oct 30, 2014 (NCT02247349)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bms-986012

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06646276Phase 3Jan 31, 2025Bristol-Myers Squibb
NCT04702880Phase 2Mar 17, 2021Bristol-Myers Squibb
NCT02949895Phase 1Nov 29, 2016Bristol-Myers Squibb
NCT02815592Phase 1/Phase 2 (Phase 2)Oct 1, 2016Bristol-Myers Squibb
NCT02247349Phase 1/Phase 2 (Phase 2)Oct 30, 2014Bristol-Myers Squibb
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit5532014
1 organizations
Page 1 / 1